Developments in cardiometabolic care for the primary care physician

The primary care team, including nurse practitioners and physician assistants, is often the first to evaluate and assess chronic conditions and interconnected comorbidities, such as steatotic liver disease, renal disease and Type 2 diabetes (T2D), using diagnostic assays. Use of evidence-based strategies for early detection and effective management of cardiovascular-kidney-metabolic (CKM) conditions is crucial for optimal patient outcomes.

Navigating the nontraditional: A look into fertility challenges and novel referral indications

Hear our subject matter experts share fertility-focused case studies that highlight the challenges and available options for nontraditional families, novel referral indications and how genetic counselors can support patients.

Society for Immunotherapy of Cancer (SITC 2024)

Antibody-drug conjugate (ADC): Navigating complex cancer therapy development

Support with developing an ADC targeted chemotherapy and CDx enabled a sponsor to navigate therapy complexity, global trial design and patient selection for a breakthrough cancer treatment.

nAbCyte™ CDx: One-time treatment. Zero room for error.

An estimated 6,000 people  in the United States live with hemophilia B. nAbCyte—the first cell-based CDx for gene therapy—offers new hope in delivering the right treatment to the right patients.

pTau217: Providing critical Alzheimer's diagnosis with key biomarker data

Every 3.2 seconds, someone globally is diagnosed with Alzheimer’s. pTau217—Labcorp’s simple and highly accurate blood-based test—offers clear answers to accelerate new, needed therapies.

Early phase development solutions: Accelerating answers for a global pandemic

A quick response to the COVID-19 pandemic helped a sponsor reduce their IND program from 12 to 5 months. With Labcorp Phase I and II trial work support, the sponsor achieved FDA emergency use authorization.

Personalized Medicine Coalition Conference​ (PMC 2024)

Antibody-drug conjugate bioanalysis: A case study in stability, matrix effects and recovery

APA 2024 -- Antibody-drug conjugates (ADCs) are an increasingly popular approach to selectively deliver a drug, the “payload”, to target cells or tissues with minimal off-target effects. A proprietary ADC with a self-immolative linker is being investigated. Three bioanalytical assays in nonhuman primate (NHP) plasma are to be developed: Total antibody, free payload and conjugated payload. 

LNP vaccine formulation screening for cellular uptake using BODIPY-labelled lipid nanoparticles

CPI RNA Vaccines and Therapeutics Conference 2024 -- RNA vaccines, comprising a mRNA encapsulated in a lipid nanoparticle (LNP), are a new modality for rapid development of synthetic prophylactic and therapeutic vaccines. The LNP acts as a device to deliver the RNA payload into the cell cytoplasm for translation of the transgene; moreover, the precise formulation of cationic/ionisable lipid, phospholipid, PEGylated lipid and cholesterol can affect the LNP cellular interaction. Crucial to the mRNA delivery is cellular uptake and escape from the endosomal compartment. To evaluate the effects of formulation components on cell uptake, a cell-based assay using 4,4-difluoro-4-bora-3a,4a-diaza-s-indacene (BODIPY)-labelled LNPs has been developed. Using a microfluidic production process, BODIPY-cholesterol has been incorporated into a range of lipid nanoparticle formulations as a potential screen for evaluating LNP formulations and cell uptake.